




A Clinical Stage Next Generation Stem Cell Therapeutics Company

Investor Presentation
May 2024



Important information

Summary information

This Presentation contains summary information about Cynata Therapeutics Limited and its subsidiaries (CYP) which is current as at 6 May 2024. This Presentation should be read in conjunction with CYP's other periodic and continuous disclosure information lodged with the Australian Securities Exchange (ASX), which are available at www.asx.com.au.

Not an offer

This Presentation is not a prospectus, product disclosure statement or other offering document under Australian law (and will not be lodged with the ASIC) or any other law. This Presentation is for information purposes only and is not an invitation or offer of securities for subscription, purchase or sale in any jurisdiction. The release, publication or distribution of this Presentation (including an electronic copy) outside Australia may be restricted by law. If you come into possession of this Presentation, you should observe such restrictions. Any non-compliance with these restrictions may contravene applicable securities laws.

Not investment advice

This Presentation does not constitute investment or financial product advice (nor tax, accounting or legal advice) or any recommendation by CYP or its advisers to acquire CYP securities. This Presentation has been prepared without taking account of any person's individual investment objectives, financial situation or particular needs. Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own investment objectives, financial situation and needs and seek legal, accounting and taxation advice appropriate to their jurisdiction. CYP is not licensed to provide financial product advice in respect of CYP securities.

Investment risk and past performance

An investment in CYP securities is subject to known and unknown risks, some of which are beyond the control of CYP and its directors. CYP does not guarantee any particular rate of return or performance of CYP. Past performance cannot be relied upon as an indicator of (and provides no guidance as to) future CYP performance including future share price performance.

Financial data

All financial information in this Presentation is in Australian currency (A\$) unless otherwise stated. This Presentation contains historical financial information based on the Company's results for the quarter to 31 March 2024. This information is disclosed in the Appendix 4C report lodged with the ASX on 30 April 2024. Any discrepancies between totals and sums of components in tables and figures in this Presentation are due to rounding.

Forward-looking statements

This Presentation contains certain 'forward looking statements', which can generally be identified by the use of forward looking words such as 'expect', 'anticipate', 'likely', 'intend', 'should', 'could', 'may', 'predict', 'plan', 'propose', 'will', 'believe', 'forecast', 'estimate', 'target', 'outlook', 'guidance', 'potential' and other similar expressions. The forward looking statements contained in this Presentation are not guarantees or predictions of future performance and involve known and unknown risks and uncertainties and other factors, many of which are beyond the control of CYP, its directors and management, and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct. There can be no assurance that actual outcomes will not differ materially from these forward looking statements. A number of important factors could cause actual results or performance to differ materially from the forward looking statements. No representation or warranty, express or implied, is made as to the accuracy, likelihood of achievement or reasonableness of any forecasts, prospects, returns or statements in relation to future matters contained in this Presentation. The forward looking statements are based on information available to CYP as at the date of this Presentation. Except as required by law or regulation (including the ASX Listing Rules), CYP and its directors, officers, employees, advisers, agents and intermediaries undertake no obligation to provide any additional or updated information whether as a result of new information, future events or results or otherwise. You are strongly cautioned not to place undue reliance on forward-looking statements, particularly in light of the current economic climate and the significant volatility, uncertainty and disruption caused by the outbreak of COVID-19.

Industry and Market data

Certain market and industry data used in connection with this Presentation may have been obtained from research, surveys or studies conducted by third parties, including industry or general publications. Neither CYP nor its representatives have independently verified any such market or industry data provided by third parties or industry or general publications.

Disclaimer

To the maximum extent permitted by law, CYP and its advisers, affiliates, related bodies corporate, directors, officers, partners, employees and agents (**Related Persons**) exclude and disclaim all liability, including without limitation for negligence, for any expenses, losses, damages or costs arising from this Presentation or reliance on anything contained in or omitted from it. To the maximum extent permitted by law, CYP and its Related Persons make no representation or warranty, express or implied, as to the currency, accuracy, reliability or completeness of information in this Presentation and disclaim any obligation or undertaking to release any update or revision to the information in this Presentation to reflect any change in expectations or assumptions. Statements made in this Presentation are made only as at the date of this Presentation. The information in this Presentation remains subject to change without notice.

Company highlights

Revolutionary iPSC-based Cymerus™ manufacturing platform

- Effectively **limitless** quantity of **consistent, high-quality** mesenchymal stem cell (MSC) doses from a **single blood donation**
- Overcomes major obstacle to commercialisation in this highly promising field

Compelling clinical data

- **Acute graft versus host disease (aGvHD) Phase 1:** 53% complete response; 87% overall response
- **Diabetic foot ulcer (DFU) Phase 1:** 88% median wound surface area reduction vs 51% in controls¹

Rich clinical pipeline

- Three major randomised controlled clinical trial readouts upcoming:
DFU (Phase 1) – early 2025; **aGvHD** (Phase 2) – 2H 2025; and **osteoarthritis** (Phase 3) – early 2026
- New trial in kidney transplantation to commence in Q2 2024

FY 2024 – a year of progress

Completion of enrolment in two randomised controlled trials

- Phase 3 osteoarthritis – enrolment completed November 2023
- Phase 1 DFU – enrolment completed April 2024

Further encouraging clinical efficacy data

- Promising initial data from ongoing DFU trial released in February 2024


New trials adding to rich pipeline

- Global Phase 2 aGvHD trial – first patient enrolled in March 2024
- New kidney transplant trial expected to commence in Q2 2024

Senior management team strengthened

- New Chief Business Officer position created to drive next stage of commercial growth
(Dr Mathias Kroll – commenced Apr 2024)


Compelling Clinical Data




aGvHD | Phase 1 clinical trial

Product: CYP-001 (Cymerus MSCs for intravenous infusion)

First completed clinical trial worldwide with any iPSC-derived product - published in **Nature Medicine**¹



No treatment-related serious adverse events or safety concerns identified



- Subjects received 1×10^6 cells/kg (max 1×10^8 cells) or 2×10^6 cells/kg (max 2×10^8 cells) by IV infusion on D0 and D7
 - Eight subjects were enrolled in each cohort, but one subject in Cohort B withdrew prior to infusion of CYP-001
 ‡ Subject A3 showed a PR at Days 14 and 21 but died due to pneumonia on Day 28; * Subject B5 withdrew from the trial on Day 22 to commence palliative care
 1. Bloor et al. Production, safety and efficacy of iPSC-derived mesenchymal stromal cells in acute steroid-resistant graft versus host disease: a phase I, multicenter, open-label, dose-escalation study. Nat Med 2020;26:1720-1725.

DFU | Phase 1 clinical trial – initial data

Product: CYP-006TK (topical Cymerus MSC wound dressing)

- Ongoing trial in non-healing diabetic foot ulcer (DFU)
- Patients randomised to receive standard of care (SoC) or CYP-006TK for 4 weeks, followed by SoC
- In the first 16 patients enrolled in the trial (8 per group), after 10 weeks' follow-up, the median reduction in wound surface area was:
 - **87.6%** in the active CYP-006TK group
 - compared to **51.1%** in SoC group

Example of ulcer healing in patient treated with CYP-006TK:


Day 0



Day 28



Revolutionary iPSC-based Cymerus™ Manufacturing Platform




Conventional MSC process

Ongoing need for new donors




Substantial inter-donor **variability**

MSC isolation



Small number of MSCs per donation

Culture expansion



Extensive MSC culture expansion required

Major challenges:

- Logistically challenging
- Inter-donor **variability** – **inconsistent** activity in MSCs from different donors
- MSCs undergo **functional changes** during extensive culture expansion


Cymerus™ iPSC-based process

One donor, one time




Avoids inter-donor variability

Reprogramming & iPSC expansion



Effectively limitless Expansion potential

Differentiation into MSCs & culture expansion




Minimal MSC culture expansion

Advantages of **Cymerus** platform:

- **Effectively limitless** iPSC expansion potential
- **Avoids** need for new donors
- **Avoids** inter-donor variability
- **Avoids** need for extensive MSC expansion
- High level of **consistency**


Therapeutic potential of MSCs



Mesenchymal stem (or stromal) cells (MSCs):

- Promote an **immunomodulatory** environment via multifactorial mechanisms¹
- The “sensor and switcher of the immune system”²
- Promote **tissue repair and regeneration**
- Can be used **without** donor/recipient matching
- Can be **engineered** to express other functional/therapeutic molecules

Advantages of iPSC-based platform



Induced pluripotent stem cells (iPSCs):


- Mature cells from adult donors, reprogrammed to become pluripotent
 - Effectively limitless proliferation in cell culture
 - Potential to differentiate into any adult cell type (including MSCs)
 - Avoids ethical controversy associated with embryonic stem cells
- **Ideal** starting material for large scale production of cellular products

Strategic partnership with Fujifilm

- Fujifilm: one of largest healthcare conglomerates globally, with significant assets in biotechnology sector, bolstered by recent multi-billion dollar investments
- Fujifilm Cellular Dynamics Inc (FCDI: subsidiary of Fujifilm) developed the original iPSC line used in Cynata's Cymerus manufacturing process
- Parties now working towards establishing Cymerus manufacturing process at FCDI with Cynata's progress showcasing Fujifilm's iPSC platform
- Fujifilm holds a 4.5% shareholding in Cynata



Rich Clinical Pipeline
– Multiple Upcoming Data
Readouts



Advanced and diverse clinical pipeline

| | Indication | Trial phase | Market opportunity |
|------------------|---|--|-------------------------|
| Cynata Sponsored |  Acute Graft vs Host Disease (aGvHD) CYP-001 <i>(FDA Orphan Designation)</i> | Phase 2 underway | US\$600m ¹ |
| |  Diabetic Foot Ulcers (DFU) CYP-006TK | Phase 1 underway (recruitment complete) | US\$9.6bn ² |
| Partnered |  Osteoarthritis (OA) CYP-004 <i>(managed by USYD, funded by NHMRC)</i> | Phase 3 underway (recruitment complete) | US\$11.6bn ³ |
| |  Renal Transplantation (Renal) CYP-001 <i>(managed and funded by LUMC)</i> | Phase 1 approved | US\$5.9bn ⁴ |

1. Global Graft versus Host Disease Market 2019-2029 (Reflects forecast market in 2026); 2. Zion Market Research, 2019 (represents global treatment market in 2025); 3. Persistence Market Research 2018 research report: "Osteoarthritis Treatment Market: Global Industry Analysis (2012-2016) and Forecast (2017-2025) (Reflect OA market by 2025); 4. Organ Transplant Immunosuppressant Drugs Market in 2026, Grand View Research, Inc., 2019

aGvHD | Phase 2 clinical trial

Product

CYP-001 (Cymerus™ iPSC-derived MSCs for intravenous infusion)

Indication

High risk acute graft versus host disease (aGvHD)¹

Study Design

- Randomised controlled trial in ~60 adults (steroids + CYP-001 vs steroids + placebo)
- Primary objective is to assess efficacy of CYP-001 based on Overall Response Rate at Day 28

Study Conduct

- Clinical sites in USA, Europe and Australia
- Regulatory/ethics approvals secured in Australia, USA, Turkey and EU
- Numerous sites now open for recruitment, with remainder expected to open in Q2 2024
- First patient enrolled – March 2024
- Aiming to complete recruitment by end of calendar year 2024

Results

Primary evaluation results anticipated in 2H CY 2025

DFU | Phase 1 clinical trial

Product

CYP-006TK (Novel silicone dressing seeded with Cymerus™ iPSC-derived MSCs)

Indication

Non-healing diabetic foot ulcers (DFU)

Study Design

- Randomised controlled trial in ~30 adults
- Patients randomised to receive either standard of care or CYP-006TK for 4 weeks, followed by standard of care
- Primary objective is safety; efficacy measures include wound healing, pain and quality of life

Study Conduct

- Clinical sites in Australia (Adelaide and Perth)
- Recruitment complete (April 2024)
- Last patient visit expected ~September 2024

Results

- Positive initial results from first 16 patients – median reduction in wound surface area after 10 weeks was **87.6%** in CYP-006TK group compared to **51.1%** in controls (n=8 per group)
- Final results anticipated in Q4 2024 or Q1 2025

OA | Phase 3 clinical trial¹

Product

CYP-004 (Cymerus™ iPSC-derived MSCs for intra-articular injection)

Indication

Osteoarthritis (OA) of the knee (Kellgren-Lawrence Grade 2-3)

Study Design

- Randomised, double-blind placebo-controlled trial in ~320 adults
- Each participant receives 3 injections over 12 months; follow-up of 24 months from first dose
- Co-primary endpoints are reduction of knee symptoms and measure of cartilage loss

Study Conduct

- Trial conducted by University of Sydney, funded by Australian Government NHMRC grant
- Clinical centres in Australia (Sydney and Hobart)
- Recruitment complete (November 2023)
- Last patient last visit expected ~November 2025

Results

- Results anticipated in H1 CY 2026

Renal transplant | Phase 1 clinical trial

Product

CYP-001 (Cymerus™ iPSC-derived MSCs for intravenous infusion)

Indication

Prevention of kidney transplant rejection

Study Design

- ~16 patients to receive CYP-001 after kidney transplantation: cohort 1 (n=3); cohort 2 (n=3); cohort 3 (n=10)
- Trial will evaluate safety (all cohorts) and efficacy of MSCs in facilitating reduction of calcineurin inhibitors (anti-rejection medication; Cohort 3)


Study Conduct

- Trial to be conducted and funded by Leiden University Medical Center (LUMC), Netherlands
- Regulatory and ethics approvals in place; final trial start-up activities ongoing
- Aiming to commence recruitment in Q2 2024

Results

Results of Cohort 1 anticipated in late 2024

Strategy, Outlook and Corporate Overview



Research partnerships

Large body of positive preclinical data generated via R&D partnerships:

- GvHD
- Diabetic wounds
- Critical limb ischaemia
- Organ transplant rejection
- Osteoarthritis
- Respiratory disorders (including asthma, pulmonary fibrosis, acute respiratory distress syndrome)
- Sepsis
- Cardiovascular disorders (including coronary artery disease, myocardial infarction)
- Cytokine release syndrome
- Glioblastoma

Several of these studies have been published in peer-reviewed journals – see [cynata.com/science_publications](https://www.cynata.com/science_publications)

Studies conducted in partnership with leading research groups worldwide



MONASH University



THE UNIVERSITY
of
WISCONSIN
MADISON



THE UNIVERSITY OF
SYDNEY



UNSW
SYDNEY



RCSI



University of
Massachusetts
Amherst



**Cell Therapy
Manufacturing**
Cooperative Research Centre




HSCI

HARVARD STEM CELL
INSTITUTE®

criticalcare
RESEARCH GROUP

SVI
St Vincent's Institute
MEDICAL RESEARCH

Commercial partnering



Partnerships will accelerate our preclinical and clinical development programs



Reinvestment of proceeds to maximise potential of the platform



We will make Cymerus available to other regenerative medicine players – growth of the field in partnership is central to our mission

Upcoming catalysts*

Results of three randomised controlled clinical trials expected between early 2025 and early 2026

1H 2024

- Renal trial – start of enrolment

2H 2024

- Renal trial – results (Cohort A)
- aGvHD trial – completion of enrolment

1H 2025


- DFU trial – results (potentially late 2024)

2H 2025

- aGvHD trial – results

1H 2026


- OA trial - results



Corporate overview

Cynata has been listed on the Australian Securities Exchange (ASX) since 2013 (Ticker: CYP)

Shareholder distribution



Financial information


Share price (6 May 2024) A\$0.235

Shares on issue ~179m


Market capitalisation ~A\$42m

Cash¹ ~A\$9m

Substantial shareholders (>5%)



BioScience Managers is an international healthcare investment firm headquarter in Melbourne that finances and enables innovative science and technology with the potential to transform healthcare.



Fidelity International is a world leading investment and asset management firm, responsible for total client assets of >US\$750 billion, from clients across Asia Pacific, Europe, the Middle East, South America and Canada.

Board & senior management

Highly skilled and experienced senior leadership team with decades of experience



Dr Kilian Kelly
Chief Executive Officer &
Managing Director

- 20+ years' experience in biopharma R&D
- Previous roles at Biota Pharmaceuticals, Mesoblast, Amgen & AstraZeneca



Dr Geoff Brooke
Independent Non-Executive Chair

- 30+ years' experience in the healthcare investment industry
- Founder and MD of Medvest Inc and GBS Venture Partners



Dr Paul Wotton
Independent Non-Executive Director

- 30+ years' experience
- Previously CEO of Ocata Therapeutics (acquired by Astellas) and Obsidian Therapeutics
- EY Entrepreneur of the Year (NJ, 2014)



Ms Janine Rolfe
Independent Non-Executive Director

- 20+ years legal, governance and management experience across multiple sectors
- Founder of Company Matters



Dr Darryl Maher
Independent Non-Executive Director

- Former Vice President, R&D and Medical Affairs at CSL Behring
- Former President of Australian Pharmaceutical Physicians Association and Director of Vaccine Solutions



Mr Peter Webse
Company Secretary

- 25+ years company secretarial experience
- Director of Governance Corporate Pty Ltd



Dr Jolanta Airey
Chief Medical Officer

- 25+ years' experience in respiratory, rheumatology, dermatology, biologicals and listed companies
- Previously Director, Translational Development at CSL



Dr Mathias Kroll
Chief Business Officer

- 25+ years' experience in biopharmaceutical industry
- Previously held leadership positions at various institutions, including Bayer, Sanofi-Aventis and GlaxoSmithKline



Contact Us

Cynata Therapeutics Limited

Level 3, 100 Cubitt Street
Cremorne
Victoria 3121
Australia

 info@cynata.com

 www.cynata.com

 [cynatatherapeutics](https://www.facebook.com/cynatatherapeutics)

 [@cynatastemcells](https://twitter.com/cynatastemcells)

 [cynata-therapeutics](https://www.linkedin.com/company/cynata-therapeutics)